Widaplik | pharmaphorum

Skip to main content

Wednesday 17 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Widaplik

News

A male palm with a pill in the middle

George's triple therapy for hypertension hits mark in stroke

George Medicines' new triple pill for hypertension delivers a much-needed win in a phase 3 trial in haemorrhagic stroke.

News

George Medicines chief executive Mark Mallon

George gets FDA nod for first blood pressure triple therapy

George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.

Editor's Picks

AC Immune says Parkinson's drug slows progression

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

Agreement reached on EU's new pharma legislation

UK teams up with Singapore on healthtech regulation

Digital

pharmaphorum podcast Episode 231, Dr Alan Roth, Oxford Drug Design

On AI and computational support of biochemistry, with Alan R...

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Sales & Marketing

woman looking at screen

Sponsored

The AI imperative: Establishing the standard for modern clin...

The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company